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Synthesis and cytotoxicity evaluation of thiazole derivatives 
obtained from 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene- 
3-carbonitrile
Reactivity of 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene- 
3-carbonitrile towards thioglycolic acid resulted in thiazole 
derivative 1. The latter reacted with different chemical re-
agents to give thiazole, pyrano[2,3-d]thiazole and thia zo-
lo[4,5-d]thiazole derivatives. Cytotoxicity effects of the new-
ly synthesized products against six cancer cell lines, namely, 
human gastric cancer (NUGC), human colon cancer (DLD-
1), human liver cancer (HA22T and HEPG-2), human breast 
cancer (MCF) and nasopharyngeal carcinoma (HONE-1) as 
well as against a normal fibroblast cell (WI-38) were evalu-
ated. The study showed that the 4,5,6,7 tetra hy dro benzo[b]
thiophene derivatives 6a, 7, 8a,b, 9b and 10b,c were the 
most active compounds. Their potencies were attributed to 
the presence of the electron withdrawing groups.
Keywords: tetrahydrobenzo[b]thiophene, thiazole, pyra-
no[2,3-d]thiazole, thiazolo[4,5-d]thiazole, cytotoxicity, anti-
cancer activity
A number of thiazole derivatives were synthesized according to the Hantzsch thia-
zole synthesis (1), along with other methods (2–7). Heterocyclic compounds containing 
thiazole moiety were found to exhibit a wide spectrum of biological activities such as an-
tioxidant (8), antitubercular (9, 10), diuretic (11), antischizophrenia (12), antibacterial (13, 
14), anti-inflammatory (15), anti-HIV (16), antihypertensive (17), antiallergic (18), hypnotic 
(19), analgesic (20), antitumor and cytotoxic (21, 22). Thiazole moiety is present in many 
drugs such as thiamine (vitamin B1), penicillin (antibiotic), sulfathiazole (antibacterial 
drug), 2-(4-chlorophenyl)thiazole-4-ylacetic (anti-inflammatory agent), thiabendazole 
[2-(4-thiazolyl)benzimidazole] (anthelmintic and fungicide), and niridazole [1-(5-nitro-2-
thiazolyl)-2-imidazolidinone] (schistosomicidal agent) (23, 24). Some thiazole derivatives 
have been recently proven to be anticancer agents (25). In the present study, we demon-
strated the reaction of 4,5,6,7-tetrahydrobenzo[b]thiophene with thioglycolic acid to pro-
duce new thiazole derivatives incorporating thiophene moiety and studied their cytotoxic-
ity against different cancer cell lines.
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EXPERIMENTAL
General
All melting points were uncorrected and determined on an electrothermal apparatus 
(Büchi 535, Switzerland) in an open capillary tube. IR spectra (KBr discs) were recorded on 
a FTIR plus 460 IR spectrophotometer (Shimadzu, Japan). 13C NMR and 1H NMR spectra 
were recorded on a Varian Gemini-200 (200 MHz) (USA) spectrometer in DMSO-d6 as sol-
vent, using TMS as internal reference and chemical shifts (d, ppm). Mass spectra were re-
corded using a Hewlett Packard 5988 (USA) GC/MS system and GCMS-QP 1000 Ex Shi-
madzu (Japan) using EI (electron impact method). Elemental analyses were carried out on 
a Vario EL III Elemental CHNS analyzer (Elementar Analysensysteme GmbH, Germany).
Syntheses
2-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)thiazol-4(5H)-one (1). – To a solution 
of 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (1.78 g, 0.01 mol) in acetic 
acid (30 mL), thioglycolic acid (0.92 g, 0.01 mol) was added. The reaction mixture was 
heated under reflux for 3 h, then poured into ice/water and the formed solid product was 
collected by filtration and crystallized from ethanol.
2-Cyano-N-(4,5,6,7-tetrahydro-3-(4,5-dihydro-4-oxothiazol-2-yl)benzo[b]thiophen-2-yl)acet-
amide (2). – To compound 1 (2.52 g, 0.01 mol) in dimethylformamide (30 mL), ethyl cyano-
acetate (1.13 g, 0.01 mol) was added, then heated in a reflux system for 4 h and poured into 
an ice/water mixture. The formed solid product was collected by filtration and crystallized 
from dimethylformamide.
1-(4,5,6,7-Tetrahydro-3-(4,5-dihydro-4-oxothiazol-2-yl)benzo[b]thiophen-2-yl)-3-phenyl-
thiourea (3). – To the dry solid of compound 1 (2.52 g, 0.01 mol) in 1,4-dioxane (35 mL) con-
taining a catalytic amount of triethylamine (0.50 mL), phenylisothiocyanate (1.35 g, 0.01 
mol) was added. The whole reaction mixture was heated under reflux for 4 h, then poured 
into an acidified ice/water mixture. The formed solid product was collected by filtration 
and crystallized from 1,4-dioxane.
1-(3-(5-(2-Phenylhydrazono)-4,5-dihydro-4-oxothiazol-2-yl)-4,5,6,7-tetrahydrobenzo[b]
thiophen-2-yl)-3-phenylthiourea (4). – To a cold solution (0–5 oC) of compound 3 (3.87 g, 0.01 
mol) in ethanol (50 mL) containing sodium hydroxide (0.40 g, 0.01 mol), benzenediazonium 
chloride (0.01 mol) [prepared by adding a cold solution of sodium nitrite (0.69 g, 0.01 mol) 
in water (10 mL) to a cold solution (0–5 oC) of aniline (0.93 g, 0.01 mol) in concentrated hy-
drochloric acid (12 mL) under continuous stirring] was added under continuous stirring. 
The whole reaction mixture was left at room temperature for 1 h and the solid product 
formed was collected by filtration and crystallized from ethanol.
2-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-5-bromo-thiazol-4(5H)-one (5) – To a 
solution of compound 1 (2.52 g, 0.01 mol) in acetic acid (40 mL) at 50 oC, bromine (1.80 g, 
0.01 mol) was added dropwise. The reaction mixture was kept at room temperature for 1 
h under continuous stirring. The solid product, when poured into an ice/water mixture, 
was collected by filtration and recrystallized from acetic acid.
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2-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-7-imino-7H-pyrano[2,3-d]thiazol-5-
amine (6a) and 2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-7-imino-7H-pyrano[2,3-d]
thiazol-5-ol (6b). General procedure. – To a solution of compound 1 (2.52 g, 0.01 mol) in 1,4-di-
oxane (40 mL) containing triethylamine (0.50 mL), either malononitrile (0.66 g, 0.01 mol) or 
ethyl cyanoacetate (1.13 g, 0.01 mol) was added. The reaction mixture, in each case, was 
heated under reflux for 5 h, left to cool and then poured into an ice/water mixture contain-
ing a few drops of hydrochloric acid. The formed solid product, in each case, was collected 
by filtration and re-crystallized from 1,4-dioxane.
5-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-3-phenyl-thiazolo[4,5-d]thiazole-
2(3H)-thione (7). – To a mixture of compound 1 (2.52 g, 0.01 mol) in 1,4-dioxane (35 mL) 
containing triethylamine (0.50 mL), elemental sulfur (0.32 g, 0.01 mol) and phenylisothio-
cyanate (1.35 g, 0.01 mol) were added. The reaction mixture was heated under reflux for 5 
h and then poured into a beaker containing an acidified ice/water mixture. The solid prod-
uct was collected by filtration, dried and then recrystallized from 1,4-dioxane.
5-(2-Phenylhydrazono)-2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)thiazol-4(5H)-one 
(8a), (5E)-5-(2-(4-chlorophenyl)hydrazono)-2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)
thiazol-4(5H)-one (8b), 5-(2-(4-methoxyphenyl)-hydrazono)-2-(2-amino-4,5,6,7-tetrahydro-
benzo[b]thiophen-3-yl)thiazol-4(5H)-one (8c) and 5-(2-p-tolyl hydra zono) -2-(2-amino-4,5,6,7-tetra-
hydro ben zo[b]thiophen-3-yl)thiazol-4(5H)-one (8d). General procedure. – To a cold solution (0–5 
oC) of compound 1 (2.52 g, 0.01 mol) in ethanol (50 mL) containing sodium hydroxide (10 %, 
10 mL), a solution of either benzenediazonium chloride (0.01 mol) or p-chlorobenzenediazo-
nium chloride (0.01 mol) or p-methoxybenzenediazonium chloride (0.01 mol) or p-methyl-
benzenediazonium chloride (0.01 mol) [prepared by dissolving sodium nitrite (0.70 g, 0.01 
mol) in water (2 mL) and added to a cold solution of aniline (0.93 g, 0.01 mol), p-chloroaniline 
(1.27 g, 0.01 mol), p-methoxyaniline (1.23 g, 0.01 mol) or p-toluidine (1.07 g, 0.01 mol), contain-
ing an appropriate amount of hydrochloric acid under continuous stirring] was added un-
der continuous stirring. The solid product formed, in each case, was collected by filtration 
and dried, and then recrystallized from ethanol.
Ethyl-2-cyano-2-(2-(3-(4-oxo-4,5-dihydrothiazol-2-yl)-4,5,6,7-tetrahydrobenzo[b]thiophen-
2-yl)hydrazono)acetate (9a), (3-(4-oxo-4,5-dihydrothiazol-2-yl)-4,5,6,7-tetrahydrobenzo[b]thiophen- 
-2-yl)carbonohydrazonoyl dicyanide (9b), dimethyl-2-(2-(3-(4-oxo-4,5-dihydrothiazol-2-yl)-
4,5,6,7-tetra hydrobenzo[b]thiophen-2-yl)hydrazono)malonate (9c) and diethyl-2-(2-(3- (4- oxo-4,5-
dihydrothiazol-2-yl)-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-hydrazono)malonate (9d). General 
procedure. – To a cold solution (0–5 °C) of the diazotized compound 1 [prepared by adding a 
NaNO2 (0.69 g, 0.01 mol) solution to a cold solution of 1 (2.52 g, 0.01 mol) in acetic acid (20 mL) 
and HCl (6 mL, 18 %)], either ethyl cyanoacetate (1.13 g, 0.01 mol) or malononitrile (0.66 g, 
0.01 mol) or acetyl acetone (1.00 g, 0.01 mol) or malonic acid diethyl ester (1.60 g, 0.01 mol) 
in ethanol (20 mL) containing sodium hydroxide (1.00 g) was gradually added under stir-
ring. Upon cooling in an ice-bath, a solid product formed in each case. It was collected by 
filtration, washed with water and crystallized from ethanol.
2-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-5-benzylidenethiazol-4(5H)-one 
(10a), 5-(4-chlorobenzylidene)-2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)thiazol-
4(5H)-one (10b), 5-(4-methoxybenzylidene)-2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)
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thiazol-4(5H)-one (10c) and 5-(2-hydroxybenzylidene)-2-(2-amino-4,5,6,7-tetrahydrobenzo[b]
thiophen-3-yl)thiazol-4(5H)-one (10d). General procedure. – To a solution of compound 1 (2.52 g, 
0.01 mol) in 1,4-dioxane and a catalytic amount of piperidine (0.50 mL), either benzalde-
hyde (1.06 g, 0.01 mol) or p-chlorobenzaldehyde (1.12 g, 0.01 mol) or p-methoxy-benzalde-
hyde (1.08 g, 0.01 mol) or salicylaldehyde (1.22 g, 0.01 mol) were added. The reaction mix-
ture was heated under reflux for 5 h, then poured into an acidified ice/water mixture. The 
formed solid product, in each case, was collected by filtration and recrystallized from 
1,4-dioxane.
In vitro cytotoxic assay
Fetal bovine serum (FBS) and L-glutamine were purchased from the Gibco Invitrogen 
Company (UK). RPMI-1640 medium was purchased from Cambrex (USA). Dimethyl sulf-
oxide (DMSO), CHS-828, penicillin, streptomycin and sulforhodamine B (SRB) were pur-
chased from the Sigma Chemical Company (USA).
No experiments were done on humans. Cancer and normal human cell lines were 
purchased. Cell cultures were obtained from the European Collection of Cell Cultures 
(ECACC, Salisbury, UK) while human gastric cancer (NUGC and HR), human colon cancer 
(DLD-1), human liver cancer (HA22T and HEPG-2), human breast cancer (MCF-7), naso-
pharyngeal carcinoma (HONE-1) and normal fibroblast cells (WI-38) were kindly provided 
by the National Cancer Institute (NCI, Cairo, Egypt). Cell lines grew as monolayers and 
were routinely maintained in RPMI-1640 medium supplemented with 5 % heat inactivated 
FBS, 2 mmol L–1 glutamine and antibiotics (penicillin 100 U mL–1, streptomycin 100 µg 
mL–1), at 37 oC in a humidified atmosphere containing 5 % CO2. Exponentially growing 
cells were obtained by plating 1.5 × 105 cells mL–1 for the six human cancer cell lines, fol-
lowed by 24 h of incubation.
The prepared heterocyclic compounds were evaluated according to standard proto-
cols for their in vitro cytotoxicity (26–28) against the six human cancer cell lines: human 
gastric cancer (NUGC), human colon cancer (DLD-1), human liver cancer (HA22T and 
HEPG-2), human breast cancer (MCF-7) and nasopharyngeal carcinoma (HONE-1), as well 
as normal fibroblast cells (WI-38).
The reference compound was (Z)-(6-(4-chlorophenoxy)hexyl)-3-cyano-2-(pyridin-4-
yl)guanidine (CHS-828), which is an antitumor agent. The effect of vehicle solvent (DMSO) 
on the growth of these cell lines was evaluated in all experiments by exposing untreated 
control cells to the maximum concentration (0.5 %) of DMSO used in each assay.
RESULTS AND DISCUSSION
Chemistry
The reaction of 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile with 
thioglycolic acid gave the thiazole derivative 1. The structure of compound 1 was con-
firmed on the basis of analytical and spectral data. Thus, the 1H NMR spectrum showed 
the presence of multiplets at δ 1.69–1.75 and δ 2.50–2.57 ppm for the four CH2 groups of 
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the cyclohexene ring, a singlet at δ 
3.90 ppm for CH2 and a singlet at δ 
6.91 ppm for NH2. In addition, the 
13C NMR spectrum revealed four 
signals at δ 21.68, 23.23, 23.43, 23.96 
ppm for four CH2 groups in cyclo-
hexene, a signal at δ 38.93 ppm for 
the CH2 thiazole moiety. Another 
four signals at δ 126.89, 130.45, 
131.05, 146.64 ppm were for the thio-
phene ring, a signal at δ 162.67 ppm 
for thiazole C=N and a signal at δ 
168.02 ppm for the C=O group. Also, 
compound 1 reacted with ethyl cya-
noacetate in dimethylformamide to 
give the N-cyanoacetamido deriva-
tive. In addition, compound 1 react-
ed with phenyl isothiocyanate to 
give the N-phenylthiourea deriva-
tive 3. 1H NMR spectrum of com-
pound 3 showed two multiplets, at δ 
1.74–1.82 and 2.48–2.56 ppm, for the 
four CH2 groups of the cyclohexene 
moiety, a singlet at δ 3.56 ppm for 
the thiazole CH2 group, a multiplet 
at δ 6.90–7.51 ppm for the phenyl 
ring and two singlets at δ 9.76 and 
11.48 ppm for two NH groups. 
Moreover, the mass spectrum re-
vealed m/z at 388 [M+1]+, m/z at 387 
[M]+ and m/z at 77 [C6H5]+ for the 
phenyl moiety. Compound 3 reacted 
with benzenediazonium chloride in 
a basic ethanolic solution at 0–5 oC 
to give the phenylhydrazo deriva-
tive 4. 
Compound 1 reacted with bro-
mine in an acetic acid solution to af-
ford the 5-bromothiazole derivative 
5. In addition, compound 1 reacted 
with either ethyl cyanoacetate or 
malononitrile in 1,4-dioxane and in 
the presence of a catalytic amount of 
triethylamine to give the pyrano[2,3-
d]thiazole-2-yl)benzo[b]thiophene 
derivatives 6a and 6b, respectively. 
Analytical and spectral data of com-
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pounds 6a,b were consistent with their respective structures. Thus, the 1H NMR spec-
trum of 6a (as an example) showed two multiplets at δ 1.68-1.95 and 2.33-2.55 ppm for four 
CH2 groups of the cyclohexene ring, a singlet at δ 6.92 ppm for pyran CH, two singlets at 
δ 7.09 and 7.25 ppm (D2O exchangeable) for two NH2 groups and a singlet at δ 11.46 ppm 
for the NH group. The 13C NMR spectrum showed four signals at δ 22.90, 23.23, 23.43, 23.96 
ppm for four CH2 groups in the cyclohexene ring, a signal at δ 66.31 ppm for the pyran 
carbon moiety, four signals at δ 126.90, 130.46, 131.05, 140.00 ppm for the thiophene carbon 
ring, a signal at δ 146.63 ppm for the thiazole C=N and four signals at δ 152.00, 162.67, 
164.00, 168.03 ppm for the pyran ring.
Further, compound 1 underwent the Hantzch reaction (1) through its reaction with 
elemental sulfur and phenylisothiocyanate to give the 3-phenylthiazolo[4,5-d]thiazole de-
rivative 7. The structure of the latter product was based on its analytical and spectral data 
(see experimental section and Tables I and II).
Compound 1 showed high reactivity towards diazonium salts; thus, it reacted with 
any of the diazonium salts, namely, benzenediazonium chloride, 4-chlorobenzenediazo-
nium chloride, 4-methoxybenzenediazonium chloride or 4-methylbenzenediazonium 
Scheme 1
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chloride, at 0–5 oC to give the arylhydrazo derivatives 8a-d, respectively. On the other 
hand, the 2-amino group present in the tetrahydrobenzo[b]thiophene underwent diazoti-
zation and coupling with active methylene reagents. A solution of compound 1 in acetic/
hydrochloric acid, when treated with sodium nitrite, gave the intermediate diazonium 
salt. The latter was coupled with any of ethyl cyanoacetate, malononitrie, acetylacetone or 
ethyl acetoacetate to give the hydrazone derivatives 9a-d, respectively. Finally, the reaction 
of compound 1 with any of benzaldehyde, 4-chlorobenzaldehyde, 4-methoxybenzaldehyde 
or salicylaldehyde afforded the corresponding arylidene derivatives 10a-d, respectively.
Synthetic pathways are presented in Schemes 1-3 and physicochemical and spectral 
data of the synthesized compounds are given in Tables I and II. Cytotoxicity of the newly 
synthesized products is displayed in Table III.
Scheme 2
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Evaluation of in vitro cytotoxic activity
The prepared heterocyclic compounds were tested against six human cancer cell lines, 
human gastric cancer (NUGC), human colon cancer (DLD-1), human liver cancer (HA22T 
and HEPG-2), human breast cancer (MCF-7) and nasopharyngeal carcinoma (HONE-1), as 
well as against normal fibroblast cells (WI-38).
The effects of the newly prepared compounds on six cancer cell lines are presented in 
Table III. Some heterocyclic compounds exerted marked cytotoxicity against most of the 
cancer cell lines tested (IC50 20–100 nmol L–1). Normal fibroblasts cells (WI-38) were affected 
to a much lesser extent (IC50 > 100 nmol L–1). It was found that some compounds showed 
cytotoxicity even higher than the reference CHS-828. Thus, compounds 5, 7, 8a, 9b and 10b 
showed high cytotoxicity towards NUGC, 8a being of comparable activity to the reference 
drug. Compounds 3, 4, 5, 6b, 8a, 8b, 8d, 9a and 9d showed high cytotoxicity against DLD-1, 
with the most active 7, 9b and 10b with IC50 markedly lower than that of CHS-828. The same 
applies to compounds 6a, 9b and 9c against HA22T. Moreover, compounds 3, 4, 7, 8a, 8b, 8d, 
9b, 9d, 10a and 10b showed higher cytotoxicity against HEPG-2 than the reference drug. In 
the case of HONE-1, 8b could be considered to be of comparable activity to CHS-828, while 
compounds 10c and 8b showed cytotoxicity comparable to CHS-828 against MCF-7.
Compound 8a was the most active towards the NUGC cancer cell line, compound 10b 
for DLD-1, compound 6a for HA22T, compound 8b for HEPG-2 and HONE-1 and finally 
compound 10c for MCF-7, all compared to the standard reference CHS-828. It is important 
to mention that most of the newly synthesized products showed either no or low cytotoxic-
ity towards the normal cell line WI-38.
Scheme 3
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Structure activity relationship
It is clear from the results in Table III that the thiazole moiety was crucial for the cy-
totoxic effect of cyclic compounds 1-10a-d. Compounds 3, 4, 5, 6a, 7, 8a, 8b, 8d, 9b-d, 10b 
and 10c exhibited a marked cytotoxic effect against the different cancer cell lines with 
Table III. Cytotoxicity of the newly synthesized products against six cancer cell lines and a normal fibroblast cell
Compd.
IC50 (nmol L–1)a,b
NUGC DLD-1 HA22T HEPG-2 HONE-1 MCF-7 WI-38
1 2101±86 2432±59 2358±80 1350±63 2180±58 1140±58 NA
2 3138±13 2366±14 2228±12 2130±69 1584±79 326±94 650±77
3 549±80 220±68 318±35 150±42 248±59 291±48 120±22
4 201±12 127±17 118±22 219±18 1170±22 1029±34 NA
5 38±18 163±38 120±68 3744±13 441±38 1264±64 860±59
6a 122±32 3210±96 59±22 1245±39 1140±60 1130±84 NA
6b 228±49 569±42 213±70 1112±59 2052±60 2011±84 632±55
7 48±16 55±12 128±80 128±42 248±59 128±77 838±48
8a 23±80 220±44 183±68 224±29 487±38 390±90 NA
8b 350±57 116±38 290±73 120±38 26±12 48±14 NA
8c 2116±21 2765±21 2838±17 3220±32 2440±24 2239±16 NA
8d 320±59 749±36 194±57 499±29 2871±17 840±68 NA
9a 537±75 440±38 1165±70 2766±12 6273±32 2533±21 419±78
9b 55±25 48±12 87±22 350±32 449±43 290±43 NA
9c 1135±76 2183±21 89±39 1220±49 2180±80 2120±69 NA
9d 302±67 143±94 173±48 392±66 80±55 284±44 NA
10a 1105±54 2460±17 2160±21 214±84 380±90 1086±29 NA
10b 80±22 24±18 160±53 284±79 130±68 73±42 872
10c 2265±60 2139±54 2257±73 2177±69 2250±12 18±80 262±52
10d 1232±69 1166±79 2225±94 2216±13 326±79 1286±87 NA
CHS-828 25±10 2315±13 2067±13 1245±69 15±60 18±70 NA
DLD-1 – colon cancer, HA22T – liver cancer, HEPG-2 – liver cancer, HONE-1 – nasopharyngeal carcinoma, MCF-7 – 
breast cancer, NA – not active, NUGC – gastric cancer, WI-38 – normal fibroblast cells
a Drug concentration required to inhibit tumor cell proliferation by 50 % after continuous exposure for 48 h; CHS-828 
was used as positive control; DMSO 0.5 % negative control.
b Mean ± SEM, n = 3.
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IC50’s in the nanomolar range. Compound 3 showed high cytotoxicity against the six cell 
lines and showed some activity against the normal cell line WI-38. Reactivity of compound 
3 was attributed to the presence of thiazole together with the N-phenylthiourea moiety. On 
the other hand, compound 5 showed high cytotoxicity against NUGC, HA22T and DLD-1 
cell lines with IC50 38, 120 and 163 nmol L–1. The presence of two cyano groups in com-
pound 9b was probably responsible for its higher activity compared to compounds 9a, 9c 
and 9d. It is obvious that compound 10b showed higher cytotoxicity than 10a, 10c and 10d 
due to the presence of the Cl group. In conclusion, based on the presented data, the pres-
ence of an electron withdrawing group enhanced the potency of the compound.
CONCLUSIONS
Briefly, we have reported the synthetic strategies for the synthesis of new thiazole 
derivatives starting from 2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)thiazol-
4(5H)-one (1). The newly prepared compounds were studied for their anticancer activities 
on six human cancer cell lines and a normal human cell line. The data showed that the 
pyrano[2,3-d]thiazole derivative (6a), thiazolo[4,5-d]thiazole derivative (7), 2-(2-amino-
4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)thiazole derivatives (8a,b, 10b,c) and the 
4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)carbonohydrazonoyl derivative (9b) were most ac-
tive against all the tested cancer cell lines. Taking into account their non-toxicity towards 
the normal cell line, compounds 6a, 8a, 8b and 9b might be considered to be of potential 
therapeutic assistance.
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